Cohance Lifesciences Company Description

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally.

The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals.

It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025.

The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited.

Cohance Lifesciences Limited

Country	India
Founded	1989
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,212
CEO	Vetukuri Venkata Naga Kali Vara Raju

Contact Details

Address: A-Wing, Galaxy Towers Hyderabad, 500081 India
Phone	91 40 2354 9414
Website	cohance.com

Stock Details

Ticker Symbol	COHANCE
Exchange	National Stock Exchange of India
Fiscal Year	April - March
Reporting Currency	INR
ISIN Number	INE03QK01018
SIC Code	2834

Key Executives

Name	Position
Yann D'Herve	Chief Executive Officer of CDMO Business
Vivek Sharma CPA	Executive Chairman
Himanshu Agarwal	Chief Financial Officer
Cyndrella Carvalho	Head of Investor Relations
Dr. K. Nagendra Babu Ph.D.	Chief Quality and Compliance Officer
Gaurav Narain Bahadur	Chief Human Resources Officer
Dr. Declan Ryan Ph.D.	Chief Commercial Officer
Gunjan Singh	Business Head of API
Sunder Venkatraman	Vice President of Corporate Affairs